Agios Pharmaceuticals Inc (AGIO)

Agios Pharmaceuticals Inc (AGIO) Q1 2021 Earnings Call Transcript
April 29, 2021 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call Transcrip
April 29, 2021 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc (AGIO) Q4 2020 Earnings Call Transcript
Feb. 25, 2021 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q4 2020 Results - Earnings Call Transcri
Feb. 25, 2021 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
Nov. 6, 2020 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc (AGIO) Q3 2020 Earnings Call Transcript
Nov. 5, 2020 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcrip
July 30, 2020 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript
July 30, 2020 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc.'s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call Transcr
April 30, 2020 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc (AGIO) Q4 2019 Earnings Call Transcript
Feb. 13, 2020 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q4 2019 Results - Earnings Call Transcrip
Feb. 13, 2020 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc (AGIO) Q3 2019 Earnings Call Transcript
Nov. 1, 2019 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
Oct. 31, 2019 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript
Aug. 5, 2019 | Price: Free! | Source: Motley Fool

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2019 Results - Earnings Call Transcript
Aug. 1, 2019 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q1 2019 Results - Earnings Call Transcript
May 2, 2019 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2018 Results - Earnings Call Transcript
Feb. 14, 2019 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) CEO David Schenkein on Q3 2018 Results - Earnings Call Transcrip
Nov. 1, 2018 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO Dr. David Schenkein on Q4 2017 Results - Earnings Call Transcript
Feb. 14, 2018 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2017 Results - Earnings Call Transcript
Nov. 1, 2017 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2017 Results - Earnings Call Transcript
Aug. 8, 2017 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q1 2017 Results - Earnings Call Transcript
May 4, 2017 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q4 2016 Results - Earnings Call Transcript
Feb. 16, 2017 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2016 Results - Earnings Call Transcript
Nov. 3, 2016 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2016 Results - Earnings Call Transcript
Aug. 4, 2016 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q1 2016 Results - Earnings Call Transcript
May 6, 2016 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q4 2015 Results - Earnings Call Transcript
Feb. 18, 2016 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2015 Results - Earnings Call Transcript
Nov. 5, 2015 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2015 Results - Earnings Call Transcript
Aug. 6, 2015 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q1 2015 Results - Earnings Call Transcript
May 7, 2015 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q4 2014 Results - Earnings Call Transcript
Feb. 17, 2015 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
Nov. 8, 2014 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2014 Results - Earnings Call Transcript
Aug. 9, 2014 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc. - Business Update Call Transcript
June 16, 2014 | Price: $1.00 | Source: Earnings Impact

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q1 2014 Results - Earnings Call Transcript
May 8, 2014 | Price: Free! | Source: Seeking Alpha

Agios' CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 6, 2014 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 9, 2013 | Price: Free! | Source: Seeking Alpha

Agios Pharmaceuticals Inc Earnings Conference Call Transcript
Nov. 7, 2013 | Price: $106.00 | Source: Thomson

Agios Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sept. 11, 2013 | Price: $54.00 | Source: Thomson

Recent filings

Statement of changes in beneficial ownership of securities - June 11, 2021

Agios Pharmaceuticals: Agios Presents Positive Results From Phase 2 Study Of Mitapivat In - June 11, 2021

Statement of changes in beneficial ownership of securities - June 9, 2021

Statement of changes in beneficial ownership of securities - June 2, 2021

Statement of changes in beneficial ownership of securities - June 2, 2021

Statement of changes in beneficial ownership of securities - June 2, 2021

Statement of changes in beneficial ownership of securities - June 2, 2021

Agios Pharmaceuticals Inc director just picked up 1,686 shares - June 2, 2021

Statement of changes in beneficial ownership of securities - June 2, 2021

Agios Pharmaceuticals Inc director just disposed of 1,729 shares - June 2, 2021

Agios Pharmaceuticals Inc director was just granted 10,473 options and restricted shares - May 24, 2021

Agios Pharmaceuticals Inc director was just granted 10,473 options and restricted shares - May 24, 2021

Agios Pharmaceuticals Inc director was just granted 10,473 options and restricted shares - May 24, 2021

Statement of changes in beneficial ownership of securities - May 24, 2021

Agios Pharmaceuticals Inc director was just granted 10,473 options and restricted shares - May 24, 2021

Agios Pharmaceuticals Inc director was just granted 10,473 options and restricted shares - May 24, 2021

Agios Pharmaceuticals Inc director was just granted 10,473 options and restricted shares - May 24, 2021

Submission of Matters to a Vote of Security - May 21, 2021

Agios Pharmaceuticals Inc's Chief Commercial Officer just disposed of 3,462 shares - May 18, 2021

Agios Pharmaceuticals: Fee Computed On Table Below Per Exchange Act Rules - May 10, 2021

Quarterly report [Sections 13 or 15(d)] - May 7, 2021

Agios Pharmaceuticals Inc Just Filed Its Quarterly Report: Loss per ShareBasic ... - April 29, 2021

Current report, items 2.02 and 9.01 - April 29, 2021

Agios Pharmaceuticals Inc's Chief Medical Officer just cashed-in 17,611 options - April 21, 2021

Agios Pharmaceuticals Inc's Principal Accounting Officer just disposed of 1,118 shares - April 20, 2021

Agios Pharmaceuticals Inc's Principal Accounting Officer just disposed of 991 shares - April 16, 2021

Agios Pharmaceuticals Inc's Chief Scientific Officer just picked up 2,246 shares - April 15, 2021

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - April 8, 2021

Other definitive proxy statements - April 8, 2021

Agios Pharmaceuticals: Unaudited Pro Forma Financial Information - April 6, 2021

CELGENE ALPINE INVESTMENT CO., LLC just issued a filing suggesting it has sold all of its Agios Pharmaceuticals Inc - April 5, 2021

Agios Pharmaceuticals: Agios Announces Closing Of Oncology Business Sale To Servier - April 2, 2021

Agios Pharmaceuticals Inc's Chief Commercial Officer just disposed of 2,700 shares - March 16, 2021

Statement of acquisition of beneficial ownership by individuals - March 10, 2021

Agios Pharmaceuticals: Agios Reports Fourth Quarter And Full Year 2020 Financial Results - Feb. 25, 2021

Securities to be offered to employees in employee benefit plans - Feb. 25, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - Feb. 25, 2021

Agios Pharmaceuticals Inc's Principal Accounting Officer just picked up 493 shares - Feb. 24, 2021

Agios Pharmaceuticals Inc's Chief Commercial Officer just picked up 510 shares - Feb. 24, 2021

Agios Pharmaceuticals Inc's Chief Medical Officer just picked up 2,348 shares - Feb. 24, 2021

Agios Pharmaceuticals Inc director just picked up 1,953 shares - Feb. 24, 2021

Agios Pharmaceuticals Inc's Chief Executive Officer just picked up 7,935 shares - Feb. 17, 2021

Agios Pharmaceuticals Inc's Chief Medical Officer just picked up 4,681 shares - Feb. 17, 2021

Agios Pharmaceuticals Inc's Chief Commercial Officer just picked up 6,672 shares - Feb. 17, 2021

Agios Pharmaceuticals Inc director just picked up 5,585 shares - Feb. 17, 2021

Agios Pharmaceuticals Inc's Principal Accounting Officer just picked up 1,118 shares - Feb. 17, 2021

Agios Pharmaceuticals Inc's Chief Scientific Officer was just granted 55,000 options and restricted shares - Feb. 12, 2021

BB Biotech AG just provided an update on share ownership of Agios Pharmaceuticals Inc - Feb. 12, 2021

Agios Pharmaceuticals Inc's Principal Accounting Officer was just granted 8,883 options and restricted shares - Feb. 12, 2021

Agios Pharmaceuticals Inc's Chief Financial Officer was just granted 55,000 options and restricted shares - Feb. 12, 2021

Agios Pharmaceuticals Inc's Chief Medical Officer was just granted 55,000 options and restricted shares - Feb. 12, 2021

Agios Pharmaceuticals Inc's Chief Executive Officer was just granted 163,000 options - Feb. 12, 2021

Agios Pharmaceuticals Inc's Chief Commercial Officer was just granted 55,000 restricted shares - Feb. 12, 2021

Definitive proxy statement relating to merger or acquisition - Feb. 11, 2021

The Vanguard Group just provided an update on share ownership of Agios Pharmaceuticals Inc - Feb. 10, 2021

Statement of acquisition of beneficial ownership by individuals - Feb. 8, 2021

Wellington Management Company LLP just provided an update on share ownership of Agios Pharmaceuticals Inc - Feb. 3, 2021

Preliminary proxy statements relating to merger or acquisition - Jan. 29, 2021

Agios Pharmaceuticals: Index To Consolidated Financial Statements - Jan. 29, 2021

Agios Pharmaceuticals: Agios Announces Phase 3 ACTIVATE-T - Jan. 26, 2021

Agios Pharmaceuticals Inc's Chief Commercial Officer just declared owning 5,875 shares of Agios Pharmaceuticals Inc - Jan. 25, 2021

Agios Pharmaceuticals: Fee Computed On Table Below Per Exchange Act Rules - Jan. 12, 2021

Agios Pharmaceuticals: Results Of Operations And Financial Condition - Jan. 11, 2021

Agios Pharmaceuticals: Agios Highlights 2021 Milestones To Accelerate And Expand Its Genetically Defined Disease Portfolio And Drive Near- And Long-Term Value Creation - Jan. 11, 2021

Agios Pharmaceuticals: Fee Computed On Table Below Per Exchange Act Rules - Dec. 23, 2020

Entry into a Material Definitive - Dec. 22, 2020

Agios Pharmaceuticals: Entry Into A Material Definitive Agreement - Dec. 22, 2020

Current report, items 7.01, 8.01, and 9.01 - Dec. 21, 2020

Agios Pharmaceuticals: Fee Computed On Table Below Per Exchange Act Rules - Dec. 21, 2020

Agios Pharmaceuticals: Fee Computed On Table Below Per Exchange Act Rules - Dec. 21, 2020

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - Dec. 21, 2020

Agios Pharmaceuticals: Agios Announces Updated Data From Phase 1 Study Of Mitapivat, - Dec. 7, 2020

Agios Pharmaceuticals Inc's Chief Financial Officer just picked up 4,046 shares - Dec. 7, 2020

Sorry, no schedule available for this company

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress - June 11, 2021

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress - June 11, 2021

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress - May 12, 2021

Agios Reports Business Highlights and First Quarter 2021 Financial Results - April 29, 2021

Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021 - April 15, 2021

Agios Announces Closing of Oncology Business Sale to Servier - April 1, 2021

Agios Shareholders Approve Sale of Oncology Business to Servier - March 25, 2021

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease - March 18, 2021

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias - Feb. 26, 2021

Agios Reports Fourth Quarter and Full Year 2020 Financial Results - Feb. 25, 2021

Agios to Present at March Investor Conferences - Feb. 23, 2021

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021 - Feb. 11, 2021

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused - Jan. 26, 2021

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma - Jan. 17, 2021

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation - Jan. 11, 2021

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 - Jan. 5, 2021

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties - Dec. 21, 2020

Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease - Dec. 7, 2020

Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias - Nov. 30, 2020

Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 - Nov. 25, 2020

 


Feedback